Cutting edge discovery and development targeting
Parkinson's disease
OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developing new drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.
Our solution
OrganoTherapeutics is a spin-off project from the University of Luxembourg. We screen for novel compounds which can be therapeutic for different patient sub-groups.
Better Models
Minibrain models that recapitulate key features of Parkinson’s disease
New Screening
Concept
Focus of the screening approach on the reverse of the cellular defect rather than on specific pre-design targets
STRATIFICATION
Development of human, personalized or sub-group stratified models
INCREASED EFFICIENCY
Fuel the drug discovery phase with more compounds to treat Parkinson’s disease
ENHANCED RELEVANCE
Target more efficiently compound candidates going to the preclinical phase -> increased success rate
